Introduction
Hemostasis plays a crucial role in surgical safety and postoperative recovery. Uncontrolled bleeding can prolong operative time, increase transfusion requirements, and lead to complications such as infection or hematoma formation. With the growing variety of hemostatic agents available-ranging from gelatin sponges and oxidized cellulose to advanced polysaccharide-based powders-clinicians must carefully evaluate which material offers optimal efficacy, safety, and ease of use for specific surgical scenarios.
In this article, we present a clinical comparison of different hemostatic agents commonly used in surgery, supported by published data and in-field experience. We also examine the unique performance advantages of Surgiclean® MPH Absorbable Hemostatic Particles, a next-generation plant-based hemostat designed for rapid, safe, and complete bleeding control.
Overview of Common Hemostatic Agents
Hemostatic agents can be broadly classified into mechanical, chemical, and biologically active types.
| Category | Typical Products | Mechanism | Drawbacks |
|---|---|---|---|
| Mechanical | Gelatin sponge, collagen pad | Provide a physical barrier for platelet aggregation | May swell post-application, causing compression or adhesion |
| Chemical | Oxidized cellulose, polysaccharide powder | Promote clotting via dehydration and surface activation | May lower local pH, delaying healing |
| Biological | Fibrin sealants, thrombin-based sprays | Mimic physiological coagulation cascade | Risk of viral contamination, expensive, require refrigeration |
Recent years have witnessed increasing adoption of plant-derived absorbable hemostats due to their safety, simplicity, and biocompatibility.
Technology Behind Surgiclean® MPH Absorbable Hemostatic Particles
Surgiclean® employs a reverse phase emulsification cross-linking technology that creates a space-net microstructure (30.8–97 μm) from natural potato starch. This unique architecture ensures rapid water absorption from blood, concentrating platelets and coagulation factors locally to accelerate natural clotting.
Key performance characteristics:
Rapid onset: Clotting begins immediately upon contact.
Absorbable: Fully metabolized into CO₂ and water within 14 days.
Safe: 100% plant-based, thrombin-free, and non-pyrogenic.
Simple to use: Ready-to-apply powder form-no mixing or refrigeration required.
Versatile: Suitable for capillary, venous, and arteriolar bleeding in open or laparoscopic surgeries.
Clinical feedback from over 810,000 surgical uses worldwide reported zero adverse events, validating the product's excellent safety record.
Applications Across Surgical Specialties
Surgiclean® has shown effective outcomes in a broad range of procedures:
Cardiovascular surgery: Reduces bleeding around vascular anastomoses and tumor beds.
Liver and biliary surgery: Effective for hepatic lobectomy and transplantation sites.
Thoracic and lung surgery: Stops bleeding at lung stumps, reducing air leaks.
Gastrointestinal and colorectal surgery: Reduces postoperative drainage and tissue oozing.
Orthopedic and trauma surgery: Controls bone surface and soft tissue bleeding.
Endoscopic and minimally invasive surgery: Applicators (TQ-1 to TQ-4) enable smooth, precise powder delivery.
These applications illustrate broad-spectrum compatibility and high surgeon confidence across specialties.
Comparison with Traditional Hemostatic Powders
| Parameter | Surgiclean® MPH | Competitor |
|---|---|---|
| Source Material | 100% plant starch (potato) | Plant starch |
| Granule Size | 30.8–97 μm | 25–75 μm |
| Hemostasis Time | ≤1 minute | 1–2 minutes |
| Absorption Time | ≤14 days | ≤48 hours (partial residues may remain) |
| Biocompatibility | Excellent, non-allergenic | Good |
| Sterilization | EO sterilization | Gamma radiation |
| Applicator System | CE-marked TQ series for open/laparoscopic use | Limited types |
| Regulatory Certification | CE1023, ISO13485, NMPA, MDSAP | CE, FDA |
| Reported Adverse Events | None (810,000+ cases) | Few minor allergic reactions |
The data suggest that Surgiclean® not only matches but often exceeds the performance of global competitors while maintaining superior safety and cost-efficiency.
Global Market Outlook
According to DelveInsight, the global absorbable hemostats market is projected to grow at a CAGR of 6.47% from 2021–2026, driven by the rising demand for blood loss management, technological advancements, and recovery of surgical services post-pandemic.
As the market shifts toward biocompatible, plant-based, and rapid-acting agents, Surgiclean® MPH is positioned at the forefront of this evolution-offering clinicians and distributors a proven, CE-certified solution that aligns with future market trends.
Why Choose Surgiclean® MPH?
Clinically validated efficacy: Proven faster hemostasis and stronger clots.
Zero reported adverse events: Reliable and safe across surgical fields.
Ease of operation: No preparation needed-apply directly to the wound.
Comprehensive portfolio: From open surgery to laparoscopic procedures.
Strong market certifications: CE1023, ISO13485, and MDSAP compliance.
Explore the full product range and detailed specifications on Surgiclean® MPH Absorbable Hemostatic Powder.
Conclusion – The Future of Hemostasis in Surgery
Clinical comparisons consistently show that Surgiclean® MPH Absorbable Hemostatic Particles deliver faster hemostasis, superior biocompatibility, and complete absorption without complications. For hospitals, surgical centers, and distributors seeking a safe, effective, and easy-to-use hemostatic solution, Surgiclean® stands out as a next-generation choice.
cooperate with Singclean
If you are a medical distributor, surgical center, or clinical procurement manager, join our growing network of partners worldwide.
Contact Singclean Medical today to request samples, technical data, or distributor opportunities.